Data to be presented supports sorfequiline’s long-term outcomes data from the Phase 2 study NC-009, use in pregnant people, and early nonclinical proof of concept data in long-acting injectable (LAI) treatments
NEW YORK (November 16, 2026) —TB Alliance will present new findings on sorfequiline, its promising new investigative compound for tuberculosis (TB), and data on how BPaL (bedaquiline + pretomanid + linezolid) performed when used to treat drug-sensitive TB, at the Union Conference on Lung Health 2026, taking place November 17-20 in Rio de Janeiro, Brazil. The conference is the largest global gathering of TB researchers and advocates.
The sorfequiline findings support its potential use in TB drug regimen development inclusive of pregnant people, as a path to shorten treatment for drug-resistant TB, and to anchor Long-Acting Injectable (LAI) treatments. Eight presentations in total will feature TB Alliance research, including preclinical findings on a new investigational compound, TBAJ-587.
With drug resistance continuing to rise, TB Alliance is working to develop drugs and regimens to further shorten treatment time, while supporting countries to rapidly adopt the newest TB treatments.
“Our progress with sorfequiline and TBAJ-587 reflects the promise of TB Alliance’s pipeline to deliver shorter, simpler, and more effective TB treatments,” said Dr. Lynn Connolly, Chief Medical Officer at TB Alliance. “The Union Conference is an important opportunity to share emerging findings and to hear from clinicians, researchers, and impacted communities about how we can translate scientific advances into treatments that better meet the needs of people living with TB.” TB Alliance research will be presented at the Union Conference in the following sessions:
- Sorfequiline reproductive toxicology data supports its inclusion in TB drug regimen development inclusive of pregnant women
Wednesday, November 18, 09:48 AM – 09:55 AM (Asia IV)
Oral Presenter: Rebecca Bruning-Barry (Research Triangle Institute, United States) - Developing sorfequiline as an anchor drug for long-acting injectable treatment of active pulmonary TB
Friday, November 20, 04:59 PM – 05:07 PM (Segovia III/IV)
Oral Presenter: Todd Black (TB Alliance, United States) - Safety and efficacy of sorfequiline in combination with pretomanid and linezolid post-treatment follow up (Trial NC-009)
Wednesday, November 18, 12:00 PM – 01:00 PM (Screen 8 (2nd floor))
Poster Presenter: Morounfolu Olugbosi (TB Alliance, South Africa) - Safety and efficacy of BPaL in DS-TB participants: A sub-analysis of trial NC-009
Wednesday, November 18, 02:15 PM – 03:45 PM (Oceania VI/VII)
Oral Presenter: Morounfolu Olugbosi (TB Alliance, South Africa) - Trial NC-009: Analysis of bacteriological failures, recurrences and drug resistance
Thursday, November 19, 09:15 AM – 10:45 AM (Asia IV)
Oral Presenter: Juliano Timm (TB Alliance, United States) - A relapsing mouse model simulating the NC-009 clinical study supports the evaluation of a hybrid regimen strategy
Thursday, November 19, 09:18 AM – 09:26 AM (Asia IV)
Todd Black (TB Alliance, United States) - Targeting immunometabolism as host-directed strategy against Mycobacterium tuberculosis (MTB) infection
Thursday, November 19, 09:30 AM – 09:35 AM (Screen 9 TBScience (2nd floor))
Poster Presenter: Natalya Serbina (TB Alliance, United States) - Mechanisms of resistance of the second-generation diarylquinoline TBAJ-587 and its major metabolites
Thursday, November 19, 03:04 PM – 03:15 PM (Asia IV)
Oral Presenter: Natalya Serbina (TB Alliance, United States)